PSA Levels No Different With Exposure to Antidiabetes Meds
Regardless of PSA levels triggering biopsy, no difference in prostate cancer detection at biopsy.
Prostate Cancer
Ultrahypofractionated SBRT Prostate Cancer Radiotherapy Does Not Increase Radiotoxicities
Ultrahypofractionated SBRT can deliver radiotherapeutic doses in 2 weeks or fewer without increasing toxicity risk, according to findings from PACE-B.
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Pathogenic, Likely Pathogenic Variants Common in Prostate Cancer
Variety of ethnicities need to be included in studies of germline testing to better understand variants.
Investigating the Role of Salvage Lymph Node Dissection in Nonmetastatic CRPC
Traditionally, approaches to the management of patients with nonmetastatic CRPC following radical prostatectomy have been limited.
Prostate Cancer Salvage Combo Benefits Confirmed
A post-hoc analysis of a phase 3 trial demonstrated that adding 6 months of androgen deprivation therapy to salvage radiotherapy for recurrent prostate cancer following radical prostatectomy improves progression-free survival at 120 months.
Prostate Cancer Risk Higher Among Men With IBD
Men with ulcerative colitis may be particularly at risk for prostate cancer, according to researchers.
Everyone’s Conflicted: How Open Payments Did Little to Discourage Conflicts of Interest in Oncology
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.
The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Next post in General Oncology
